Treatment with the PPARα agonist fenofibrate improves the efficacy of CD8⁺ T cell therapy for melanoma.

ABSTRACT: Adoptive transfer of tumor antigen-specific CD8⁺ T cells can limit tumor progression but is hampered by the T cells' rapid functional impairment within the tumor microenvironment (TME). This is in part caused by metabolic stress due to lack of oxygen and glucose. Here, we report that fenofibrate treatment of human ex vivo expanded tumor-infiltrating lymphocytes (TILs) improves their ability to limit melanoma progression in a patient-derived xenograft (PDX) mouse model. TILs treated with fenofibrate, a peroxisome proliferator receptor alpha (PPARα) agonist, switch from glycolysis to fatty acid oxidation (FAO) and increase the ability to slow the progression of autologous melanomas in mice with freshly transplanted human tumor fragments or injected with tumor cell lines est

SUBMITTER: Hasanpourghadi M 

PROVIDER: S-EPMC10701456 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature